Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica

Initial criteria

• age ≥ 18 years
• used for first-line therapy
• EITHER patient ineligible for cisplatin and tumor PD-L1 tumor infiltrating immune cells covering ≥ 5% of tumor area OR ineligible for any platinum-containing chemotherapy regardless of PD-L1 expression
• prescribed by or in consultation with an oncologist

Approval duration

1 year